111 related articles for article (PubMed ID: 23113249)
1. Role of metabotropic glutamate receptors in the mechanisms of experimental parkinsonism development.
Bashkatova VG; Sudakov SK
Bull Exp Biol Med; 2012 Sep; 153(5):655-7. PubMed ID: 23113249
[TBL] [Abstract][Full Text] [Related]
2. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
Alam M; Danysz W; Schmidt WJ; Dekundy A
Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
[TBL] [Abstract][Full Text] [Related]
3. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
Breysse N; Baunez C; Spooren W; Gasparini F; Amalric M
J Neurosci; 2002 Jul; 22(13):5669-78. PubMed ID: 12097518
[TBL] [Abstract][Full Text] [Related]
4. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Marin C; Bonastre M; Aguilar E; Jiménez A
Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
[TBL] [Abstract][Full Text] [Related]
5. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
[TBL] [Abstract][Full Text] [Related]
6. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
[TBL] [Abstract][Full Text] [Related]
7. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
[TBL] [Abstract][Full Text] [Related]
8. Blockade of metabotropic glutamate receptor 5 protects against DNA damage in a rotenone-induced Parkinson's disease model.
Xia N; Zhang Q; Wang ST; Gu L; Yang HM; Liu L; Bakshi R; Yang H; Zhang H
Free Radic Biol Med; 2015 Dec; 89():567-80. PubMed ID: 26454081
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.
Gołembiowska K; Konieczny J; Wolfarth S; Ossowska K
Neuropharmacology; 2003 Sep; 45(4):484-92. PubMed ID: 12907309
[TBL] [Abstract][Full Text] [Related]
10. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats.
Ossowska K; Konieczny J; Wolfarth S; Wierońska J; Pilc A
Neuropharmacology; 2001 Sep; 41(4):413-20. PubMed ID: 11543761
[TBL] [Abstract][Full Text] [Related]
12. MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats.
Ossowska K; Konieczny J; Wolfarth S; Pilc A
Neuropharmacology; 2005 Sep; 49(4):447-55. PubMed ID: 15919101
[TBL] [Abstract][Full Text] [Related]
13. mGluR5-dependent increases in immediate early gene expression in the rat striatum following acute administration of amphetamine.
Parelkar NK; Wang JQ
Brain Res Mol Brain Res; 2004 Mar; 122(2):151-7. PubMed ID: 15010207
[TBL] [Abstract][Full Text] [Related]
14. Preproenkephalin mRNA expression in rat dorsal striatum induced by selective activation of metabotropic glutamate receptor subtype-5.
Parelkar NK; Wang JQ
Synapse; 2003 Mar; 47(4):255-61. PubMed ID: 12539198
[TBL] [Abstract][Full Text] [Related]
15. Long-Lasting Impairment of mGluR5-Activated Intracellular Pathways in the Striatum After Withdrawal of Cocaine Self-Administration.
Hoffmann HM; Crouzin N; Moreno E; Raivio N; Fuentes S; McCormick PJ; Ortiz J; Vignes M
Int J Neuropsychopharmacol; 2017 Jan; 20(1):72-82. PubMed ID: 27744406
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies.
Zhu A; Wang X; Yu M; Wang JQ; Brownell AL
J Cereb Blood Flow Metab; 2007 Sep; 27(9):1623-31. PubMed ID: 17299451
[TBL] [Abstract][Full Text] [Related]
17. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
Konieczny J; Wardas J; Kuter K; Pilc A; Ossowska K
Neuroscience; 2007 Mar; 145(2):611-20. PubMed ID: 17224239
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.
Breysse N; Amalric M; Salin P
J Neurosci; 2003 Sep; 23(23):8302-9. PubMed ID: 12967992
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effect caused by MPEP, an antagonist of metabotropic glutamate receptor mGluR5, on seizures induced by pilocarpine in 21-day-old rats.
Jesse CR; Savegnago L; Rocha JB; Nogueira CW
Brain Res; 2008 Mar; 1198():197-203. PubMed ID: 18242586
[TBL] [Abstract][Full Text] [Related]
20. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats.
Lopez S; Turle-Lorenzo N; Johnston TH; Brotchie JM; Schann S; Neuville P; Amalric M
Neuropharmacology; 2008 Sep; 55(4):483-90. PubMed ID: 18625257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
